US FDA’s Latest Breakthrough Therapy Awards Include Asthma, Alopecia Areata, And (Of Course) Oncology Therapies

New BTDs include Loxo’s RET inhibitor for RET fusion-positive lung cancer and RET mutant medullary thyroid cancer, Y-mAbs’ naxitamab for high-risk neuroblastoma, AstraZeneca/Amgen’s tezepelumab for severe asthma, and Pfizer’s JAK3 inhibitor for alopecia areata.

Sunshine

While oncologics remain the mainstay of US FDA’s flagship regulatory incentive program, the breakthrough therapy designation (BTD), recent awards illustrate how the program is encouraging development for unmet needs within big markets like respiratory disease and dermatology.

Respiratory disease, one of AstraZeneca PLC’s primary areas of focus for R&D, has now earned the company a breakthrough...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet